Molecular Theranostics LLC
Cleveland, OH
- UEI
- L1VLYM9HZNK3
- CAGE
- 72M95
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 7100 Euclid Ave Suite 152, Cleveland, OH 44103, USA
- Website
- mtheranostics.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of next-generation targeted MRI contrast agents - the objective of this research project is to develop the… | National Cancer Institute | $528,259 | |
| A peptide targeted fluorescence probe for precision surgery of head and neck cancer - abstract: the goal of this sbir… | National Institute of Dental and Craniofacial Research | $294,505 | |
| Development of peptide drug conjugates for cancer therapy - abstract the ultimate goal of this project is to develop and… | National Cancer Institute | $530,358 | |
| Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer - abstract prostate cancer is a… | National Cancer Institute | $4,000,000 | |
| Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer. | National Cancer Institute | $2,081,265 |
About Molecular Theranostics LLC
Molecular Theranostics LLC is a small, disadvantaged business registered in SAM.gov that specializes in developing advanced molecular imaging and targeted therapeutic technologies for cancer diagnostics and treatment. As an Asian-Pacific American owned limited liability company, the firm focuses on creating innovative peptide-based technologies that can improve medical imaging and precision oncology treatments. Their core competency involves designing specialized molecular probes and drug delivery systems that can enhance cancer detection and treatment across various cancer types.
The company has received multiple substantial federal grant awards from civilian research agencies, primarily the National Cancer Institute and the National Institute of Dental and Craniofacial Research, through Small Business Innovation Research (SBIR) programs. Their recent federal grant work has centered on developing targeted molecular technologies for specific cancer applications, including a fluorescence dye for head and neck cancer surgical imaging, peptide drug conjugates for treating triple-negative breast cancer, and an MRI contrast agent for differentiating prostate cancer risks. Each project demonstrates a sophisticated approach to cancer diagnostics and therapeutics, involving complex peptide synthesis, characterization of molecular probes, and preclinical/clinical testing. The grants, ranging from approximately $294,505 to $530,358, support phase I and phase II research efforts aimed at translating innovative molecular technologies from initial concept through potential clinical application, with a strong emphasis on improving cancer detection, surgical precision, and targeted treatment strategies.
Quick answers
What is Molecular Theranostics LLC's UEI?
Molecular Theranostics LLC's Unique Entity ID (UEI) in SAM.gov is L1VLYM9HZNK3.
What is Molecular Theranostics LLC's CAGE code?
Molecular Theranostics LLC's CAGE code is 72M95.
What is Molecular Theranostics LLC's primary NAICS code?
Molecular Theranostics LLC's primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Molecular Theranostics LLC located?
Molecular Theranostics LLC's physical address in SAM.gov is 7100 Euclid Ave Suite 152, Cleveland, OH 44103, USA.
Is Molecular Theranostics LLC registered in SAM.gov?
Yes. Molecular Theranostics LLC's SAM.gov registration is active through July 5, 2027.
What is Molecular Theranostics LLC's most recent federal award?
Molecular Theranostics LLC's most recent federal grant award is Development of next-generation targeted MRI contrast agents - the objective of this research project is to develop the… (R01CA297667), from National Cancer Institute, on September 1, 2026.
On GovTribe
See Molecular Theranostics LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors